Recent Updates
Recently added Catalysts
BTSG Positive Sentiment Score: 85/100

BrightSpring Health Services, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Increases Full Year 2025 Guidance LOUISVILLE, Ky.

Key Takeaway: BrightSpring Health Services, Inc. reported strong financial results for the fourth quarter and full year 2024, achieving a 28.6% increase in net revenue and a net income of $15.4 million, a significant improvement from the previous year's loss. The company also raised its revenue and Adjusted EBITDA guidance for 2025, focusing on growth while planning to streamline operations after the divestiture of its Community Living business. Despite a net loss for the full year, the overall outlook remains optimistic as BrightSpring aims to enhance its service solutions for complex health populations.

Market Sentiment Analysis

POSITIVE FACTORS

  • Fourth quarter net revenue increased by 28.6%.
  • Net income turned profit at $15.4 million compared to prior year loss.
  • Adjusted EBITDA showed growth of 17.4% in Q4.

CONCERNS & RISKS

  • Despite improvements, the company still reported a full year net loss of $20.5 million.
  • The Community Living business divestiture may lead to transitional challenges.

Full Press Release Details

BrightSpring Health Services, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Increases Full Year 2025 Guidance
LOUISVILLE, Ky., March 6, 2025 BrightSpring Health Services, Inc. ( BrightSpring or the Company ) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, today announced financial results for the fourth quarter and full year ended December 31, 2024, and increased revenue and Adjusted EBITDA1 guidance.
Financial Highlights
-Fourth quarter net revenue of $3,053 million, up 28.6% compared to $2,375 million in the fourth quarter of 2023.
-Fourth quarter net income of $15.4 million, compared to net loss of $7.2 million in the fourth quarter of 2023.
-Fourth quarter Adjusted EBITDA1 of $167 million, up 17.4% versus $143 million in the fourth quarter of 2023.
-Full year net revenue of $11,266 million, up 27.6% compared to $8,826 million in 2023.
-Full year net loss of $20.5 million, compared to net loss of $156.8 million in 2023.
-Full year Adjusted EBITDA1 of $588 million, up 9.3% versus $538 million in 2023.
oWhen excluding a certain $30 million Quality Incentive Payment (QIP) in 2023, Adjusted EBITDA was up 15.9% compared to $508 million in 2023. This certain vendor QIP program has reached its conclusion, as previously disclosed.
-On January 20, 2025, announced BrightSpring entered into a definitive agreement to divest the Community Living business to Sevita for $835 million, subject to customary closing adjustments.
-Increased 2025 Revenue and Adjusted EBITDA Guidance, excluding Community Living:
oRevenue: $11,600 - $12,100 million
oAdjusted EBITDA1: $545 - $560 million
In 2024, BrightSpring's focus on quality and third-party satisfaction scores, growth in customers and patients served, and efficiency and best practices across the organization resulted in another excellent year of both operational and financial performance, said Jon Rousseau, Chairman, President and Chief Executive Officer of the Company. I am proud of our team's commitment and capabilities that underpin these results, as well as the organization's impact throughout communities. We are enthusiastic about what's in front of us in 2025, as we further drive our mission to reach people who need the Company's beneficial service solutions. We expect the recently announced divestiture of Community Living to result in a more streamlined organization with greater capital flexibility and increased growth rates.
Fourth Quarter 2024 Financial Results
Net revenue of $3,053 million, up 28.6% compared to $2,375 million in the fourth quarter of 2023.
Gross profit of $422 million, up 14.4% compared to $369 million in the fourth quarter of 2023.
Net income of $15.4 million, compared to net loss of $7.2 million in the fourth quarter of 2023.
Adjusted EBITDA1 of $167 million, up 17.4% compared to $143 million in the fourth quarter of 2023.
Full Year 2024 Financial Results
Net revenue of $11,266 million, up 27.6% compared to $8,826 million in 2023.
Gross profit of $1,588 million, up 10.8% compared to $1,434 million in 2023. Excluding a certain $30 million receipt of QIP in 2023, gross profit growth rate was 13.2%.
Net loss of $20.5 million, compared to net loss of $156.8 million in 2023.
Adjusted EBITDA1 of $588 million, up 9.3% compared to $538 million in 2023
-When excluding a certain $30 million QIP in 2023, Adjusted EBITDA1 was up 15.9% compared to $508 million in 2023.
1Adjusted EBITDA is a non-GAAP financial measure. Please see Non-GAAP Financial Information and the end of this press release for a reconciliation of Adjusted EBITDA to net loss, the most directly comparable financial measure prepared in accordance with GAAP.
Three Months Ended Year Ended
December 31, December 31,
2024 2023 % 2024 2023 %
($ in millions)
Pharmacy Solutions Revenue $ 2,397 $ 1,785 34% $ 8,754 $ 6,522 34%
Provider Services Revenue 656 589 11% 2,512 2,304 9%
Total Revenue $ 3,053 $ 2,375 29% $ 11,266 $ 8,826 28%
Three Months Ended Year Ended
December 31, December 31,
2024 2023 % 2024 2023 %
($ in millions)
Pharmacy Solutions segment EBITDA $ 113 $ 93 22% $ 395 $ 371 6%
Provider Services segment EBITDA 99 86 16% 361 307 18%
Total Segment Adjusted EBITDA $ 212 $ 178 19% $ 755 $ 678 11%
Corporate Costs (45) (36) - (167) (140) -
Total Company Adjusted EBITDA $ 167 $ 143 17% $ 588 $ 538 9%
Full Year 2025 Financial Guidance
For the full year 2025, BrightSpring is increasing guidance, which excludes the Community Living business and the effects of any future closed acquisitions. All growth rates reflect growth from the full year 2024 revenue and Adjusted EBTIDA results, excluding the Community Living business.
-Net Revenue of $11,600 million to $12,100 million, or 15.2% to 20.1% growth over full year 2024.
oPharmacy Segment Revenue of $10,150 million to $10,600 million, or 15.9% to 21.1% growth over full year 2024.
oProvider Segment Revenue of $1,450 million to $1,500 million, or 10.0% to 13.8% growth over full year 2024.
-Adjusted EBITDA2 of $545 million to $560 million, or 18.4% to 21.7% growth over full year 2024.
A copy of the Company's fourth quarter and fiscal year 2024 earnings presentation is available on the Company's investor relations website, https://ir.brightspringhealth.com/
2A reconciliation of the foregoing guidance for the non-GAAP metric of Adjusted EBITDA to GAAP net loss cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of our control, or cannot be reasonably predicted. For the same reasons, the Company is unable to assess the probable significance of the unavailable information, which could have a material impact on its future GAAP financial results.
Webcast and Conference Call Details
BrightSpring will host a conference call today, March 6, 2025, at 8:30 a.m. Eastern Time. Investors interested in listening to the conference call are required to register online.
A live and archived webcast of the event will be available on the Events & Presentations section of the BrightSpring website at https://ir.brightspringhealth.com/. The Company has posted supplemental financial information on the fourth quarter and fiscal year 2024 results that it will reference during the conference call. The supplemental information can be found under the Events & Presentations on the Company's investor relations page.
About BrightSpring Health Services
BrightSpring Health Services provides complementary home- and community-based pharmacy and provider health solutions for complex populations in need of specialized and/or chronic care. Through the Company's service lines, including pharmacy, home health care and primary care, and rehabilitation and behavioral health, we provide comprehensive and more integrated care and clinical solutions in all 50 states to over 450,000 customers, clients and patients daily. BrightSpring has consistently demonstrated strong and often industry-leading quality metrics across its services lines while improving the quality of life and health for high-need individuals and reducing overall costs to the healthcare system.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views with respect to, among other things, our operations and financial performance. Forward-looking statements include all statements that are not historical facts. These forward-looking statements may relate to matters which include, but are not limited to, industries, business strategy, goals and expectations concerning our market position, future operations, margins, profitability, capital expenditures, liquidity and capital resources and other financial and operating information. In some cases, we have used words such as anticipate, assume, believe, continue, could, estimate, expect, intend, may, plan, potential, predict, project, future, will, seek, foreseeable, target, guidance, the negative version of these words, or similar terms and phrases to identify these forward-looking statements.
The forward-looking statements are based on management's current expectations and are not historical facts or guarantees of future performance. The forward-looking statements relate to the future and are therefore subject
to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. Our expectations, beliefs, and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that management's expectations, beliefs, and projections will result or be achieved. Actual results may differ materially from these expectations due to changes in global, regional, or local economic, business, competitive, market, regulatory, and other factors, many of which are beyond our control. We believe that these factors include but are not limited to the following:
-our operation in a highly competitive industry;
-our inability to maintain relationships with existing patient referral sources or establish new referral sources;
-changes to Medicare and Medicaid rates or methods governing Medicare and Medicaid payments for our services;
-cost containment initiatives of third-party payors, including post-payment audits;
-the implementation of alternative payment models and the transition of Medicaid and Medicare beneficiaries to managed care organizations may limit our market share and could adversely affect our revenues;
-changes in the case mix of patients, as well as payor mix and payment methodologies, and decisions and operations of third-party organizations;
-our reliance on federal and state spending, budget decisions, and continuous governmental operations which may fluctuate under different political conditions;
-changes in drug utilization and/or pricing, PBM contracts, and Medicare Part D/Medicaid reimbursement, which may negatively impact our profitability;
-changes in our relationships with pharmaceutical suppliers, including changes in drug availability or pricing;
-reliance on the continual recruitment and retention of nurses, pharmacists, therapists, caregivers, direct support professionals, and other qualified personnel, including senior management;
-compliance with or changes to federal, state, and local laws and regulations that govern our employment practices, including minimum wage, living wage, and paid time-off requirements;
-fluctuation of our results of operations on a quarterly basis;
-harm caused by labor relation matters;
-limitations in our ability to control reimbursement rates received for our services if we are unable to maintain or reduce our costs to provide such services;
-delays in collection or non-collection of our accounts receivable, particularly during the business integration process;
-failure to manage our growth effectively, which may inhibit our ability to execute our business plan, maintain high levels of service and satisfaction or adequately address competitive challenges;
-our ability to identify, successfully complete and manage acquisitions, joint ventures, and other strategic initiatives, including the pending sale of our Community Living business;
-our ability to continue to provide consistently high quality of care;
-maintenance of our corporate reputation or the emergence of adverse publicity, including negative information on social media or changes in public perception of our services;
-contract continuance, expansion and renewal with our existing customers, including renewals at lower fee levels, customers declining to purchase additional services from us, or reduction in the services received from us pursuant to those contracts;
-effective investment in, implementation of improvements to and proper maintenance of the uninterrupted operation and data integrity of our information technology and other business systems;
-security breaches, loss of data, and other disruptions, which could compromise sensitive business or patient information; cause a loss of confidential patient data, employee data or personal information; or prevent access to critical information and thereby expose us to liability, litigation, and federal and state governmental inquiries and damage our reputation and brand;
-risks related to credit card payments and other payment methods;
-potential substantial malpractice or other similar claims;
-various risks related to governmental inquiries, regulatory actions, and whistleblower and other lawsuits, which may not be entirely covered by insurance;
-our current insurance program, which may expose us to unexpected costs, particularly if we incur losses not covered by our insurance or if claims or losses differ from our estimates;
-factors outside of our control, including those listed, which have required and could in the future require us to record an asset impairment of goodwill;
-a pandemic, epidemic, or outbreak of an infectious disease;
-inclement weather, natural disasters, acts of terrorism, riots, civil insurrection or social unrest, looting, protests, strikes, or street demonstrations; and
-our inability to adequately protect our intellectual property rights.
The forward-looking statements included in this press release are made only as of the date of this press release, and we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as required by law. These factors should not be construed as exhaustive, and should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, our actual results may vary in material respects from those projected in these forward-looking statements. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Our forward- looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments, or other strategic transactions we may make.
For additional information on these and other factors that could cause BrightSpring's actual results to differ materially from expected results, please see our filings with the Securities and Exchange Commission (the SEC ), which are accessible on the SEC's website at www.sec.gov.
Non-GAAP Financial Measures
This press release contains non-GAAP financial measures, including EBITDA and Adjusted EBITDA, which are financial measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with accounting principles generally accepted in the United States, or GAAP.
EBITDA and Adjusted EBITDA have been presented in this release as supplemental measures of financial performance that are not required by, or presented in accordance with, GAAP, because we believe they assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Management also believes that these measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate and capital investments. Management uses EBITDA and Adjusted EBITDA to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish and award discretionary annual incentive compensation, and to compare our performance against that of other peer companies using similar measures.
Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone. EBITDA and Adjusted EBITDA are not GAAP measures of our financial performance and should not be considered as an alternative to net loss as a measure of financial performance or any other performance measures derived in accordance with
GAAP. Additionally, these measures are not intended to be a measure of free cash flow available for management's discretionary use as they do not consider certain cash requirements such as tax payments, debt service requirements, total capital expenditures, and certain other cash costs that may recur in the future.
Management defines EBITDA as net loss before income tax expense (benefit), interest expense, and depreciation and amortization. Management also defines Adjusted EBITDA as EBITDA, further adjusted to exclude non-cash share-based compensation, acquisition, integration and transaction-related costs, restructuring and divestiture-related and other costs, goodwill impairment, legal costs and settlements associated with certain historical matters for PharMerica, significant projects, management fees, and unreimbursed COVID-19 related costs.
The presentations of these measures have limitations as analytical tools and should not be considered in isolation, or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company. Please see the end of this press release for reconciliations of non-GAAP financial measures to the most directly comparable financial measure prepared in accordance with GAAP.
BrightSpring Contact:
BrightSpring Health Services, Inc. and Subsidiaries
Consolidated Balance Sheets
December 31, 2024 and 2023
(In thousands, except share and per share data)
December 31, 2024 December 31, 2023
Assets
Current assets:
Cash and cash equivalents $ 61,253 $ 13,071
Accounts receivable, net of allowance for credit losses 1,028,654 881,627
Inventories 640,568 402,776
Prepaid expenses and other current assets 162,579 159,167
Total current assets 1,893,054 1,456,641
Property and equipment, net of accumulated depreciation of $450,309 and $368,089 at December 31, 2024 and 2023, respectively 250,286 245,908
Goodwill 2,671,524 2,608,412
Intangible assets, net of accumulated amortization 811,482 881,476
Operating lease right-of-use assets, net 249,748 267,446
Deferred income taxes, net 5,575
Other assets 44,471 72,838
Total assets $ 5,926,140 $ 5,532,721
Liabilities, Redeemable Noncontrolling Interests, and Equity
Current liabilities:
Trade accounts payable $ 941,292 $ 641,607
Accrued expenses 356,538 492,363
Current portion of obligations under operating leases 69,665 71,053
Current portion of obligations under financing leases 12,113 11,141
Current portion of long-term debt 48,725 32,273
Total current liabilities 1,428,333 1,248,437
Obligations under operating leases, net of current portion 187,614 201,655
Obligations under financing leases, net of current portion 24,991 22,528
Long-term debt, net of current portion 2,561,858 3,331,941
Deferred income taxes, net 23,668
Long-term liabilities 71,759 91,943
Total liabilities 4,274,555 4,920,172
Redeemable noncontrolling interests 3,730 27,139
Shareholders' equity:
Common stock, $0.01 par value, 1,500,000,000 and 137,398,625 shares authorized, 174,245,990 and 117,857,055 shares issued and outstanding at December 31, 2024 and 2023, respectively $ 1,742 $ 1,179
Preferred stock, $0.01 par value, 250,000,000 authorized; no shares issued and outstanding at December 31, 2024; no shares authorized, issued or outstanding at December 31, 2023
Additional paid-in capital 1,866,850 771,336
Accumulated deficit (222,155 ) (200,319 )
Accumulated other comprehensive income 1,418 12,544
Total shareholders' equity 1,647,855 584,740
Noncontrolling interest 670
Total equity 1,647,855 585,410
Total liabilities, redeemable noncontrolling interests, and equity $ 5,926,140 $ 5,532,721
BrightSpring Health Services, Inc. and Subsidiaries
Consolidated Statements of Operations
For the three and twelve months ended December 31, 2024 and 2023
(In thousands, except per share amounts)
For the Three Months Ended For the Years Ended
December 31, December 31,
2024 2023 2024 2023
Revenues:
Products $ 2,397,059 $ 1,785,457 $ 8,754,282 $ 6,522,450
Services 655,742 589,087 2,512,190 2,303,725
Total revenues 3,052,801 2,374,544 11,266,472 8,826,175
Cost of goods 2,192,520 1,614,641 8,008,501 5,840,716
Cost of services 438,382 391,188 1,669,536 1,551,665
Gross profit 421,899 368,715 1,588,435 1,433,794
Selling, general, and administrative expenses 342,846 300,453 1,382,061 1,286,614
Operating income 79,053 68,262 206,374 147,180
Loss on extinguishment of debt 12,726
Interest expense, net 54,866 83,054 228,386 324,593
Income (loss) before income taxes 24,187 (14,792 ) (34,738 ) (177,413 )
Income tax expense (benefit) 8,783 (7,591 ) (14,217 ) (20,578 )
Net income (loss) 15,404 (7,201 ) (20,521 ) (156,835 )
Net loss attributable to noncontrolling interests (595 ) (664 ) (2,459 ) (2,232 )
Net income (loss) attributable to BrightSpring Health Services, Inc. and subsidiaries $ 15,999 $ (6,537 ) $ (18,062 ) $ (154,603 )
Net income (loss) per common share:
Income (loss) per share - basic $ 0.08 $ (0.06 ) $ (0.09 ) $ (1.31 )
Income (loss) per share - diluted $ 0.08 $ (0.06 ) $ (0.09 ) $ (1.31 )
Weighted average shares outstanding:
Basic 200,312 117,857 192,997 117,868
Diluted 213,160 117,857 192,997 117,868
BrightSpring Health Services, Inc. and Subsidiaries
Consolidated Statements of Cash Flows

Frequently Asked Questions

What were BrightSpring's Q4 2024 net revenues?

BrightSpring's Q4 2024 net revenues were $3,053 million, a 28.6% increase.

How much did BrightSpring's net income improve in Q4 2024?

In Q4 2024, BrightSpring reported a net income of $15.4 million, reversing a loss.

What is the full year 2025 revenue guidance for BrightSpring?

BrightSpring's 2025 revenue guidance is set between $11,600 million and $12,100 million.

What is BrightSpring's full year net loss for 2024?

BrightSpring reported a full year net loss of $20.5 million in 2024.

What is BrightSpring's Adjusted EBITDA for full year 2024?

The Adjusted EBITDA for BrightSpring in full year 2024 was $588 million.

Last updated: Mar 6, 2025